363 related articles for article (PubMed ID: 16840198)
41. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
42. New strategies for the treatment of acute promyelocytic leukaemia.
Mandelli F
J Intern Med Suppl; 1997; 740():23-7. PubMed ID: 9350178
[TBL] [Abstract][Full Text] [Related]
43. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare.
Ohno R; Yoshida H; Fukutani H; Naoe T; Ohshima T; Kyo T; Endoh N; Fujimoto T; Kobayashi T; Hiraoka A
Leukemia; 1993 Nov; 7(11):1722-7. PubMed ID: 8231241
[TBL] [Abstract][Full Text] [Related]
44. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
45. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
46. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group.
Fenaux P; Chastang C; Degos L
Leukemia; 1994; 8 Suppl 2():S42-7. PubMed ID: 7815836
[TBL] [Abstract][Full Text] [Related]
47. Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
Visani G; Tosi P; Cenacchi A; Manfroi S; Gamberi B; Ottaviani E; Tura S
Leuk Lymphoma; 1994 Sep; 15(1-2):143-7. PubMed ID: 7858492
[TBL] [Abstract][Full Text] [Related]
48. Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG.
Kungwankiattichai S; Owattanapanich W; Rattanathammethee T; Rattarittamrong E; Chanswangphuwana C; Polprasert C; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Prayongratana K; Sriswasdi C; Nakhakes C
Hematology; 2023 Dec; 28(1):2191462. PubMed ID: 36951362
[TBL] [Abstract][Full Text] [Related]
49. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
[TBL] [Abstract][Full Text] [Related]
50. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
[TBL] [Abstract][Full Text] [Related]
51. [Differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid].
Ohno R; Naoe T; Fukutani H
Gan To Kagaku Ryoho; 1993 Jun; 20(8):1016-21. PubMed ID: 8390226
[TBL] [Abstract][Full Text] [Related]
52. [Induction and maintenance therapy in all-trans retinoic acid with relapsed acute promyelocytic leukemia].
Takitani K; Kawamura N; Yamaguchi H; Morinobu W; Yoshida N; Watanabe K; Miyake M; Tatsumi K; Mino M
Rinsho Ketsueki; 1995 Feb; 36(2):147-52. PubMed ID: 7715086
[TBL] [Abstract][Full Text] [Related]
53. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
54. Molecular monitoring of minimal residual disease in acute promyelocytic leukemia by the polymerase chain reaction assay for the PML/RAR alpha (retinoic acid receptor-alpha) fusion transcript in patients treated with all-trans retinoic acid followed by chemotherapy.
Nemet D; Grahovac B; Labar B; Mrsić M; Radman I; Bogdanić V; Hitrec V; Zaher D; Aurer I; Sertić D
Haematologica; 1995; 80(3):238-40. PubMed ID: 7672716
[TBL] [Abstract][Full Text] [Related]
55. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
56. The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.
Fenaux P
Acta Haematol; 1993; 89 Suppl 1():22-7. PubMed ID: 8475669
[TBL] [Abstract][Full Text] [Related]
57. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
58. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy.
Thomas X; Anglaret B; Thiebaut A; Belhabri A; Treille-Ritouet D; Fiere D; Archimbaud E
Ann Hematol; 1997; 75(5-6):195-200. PubMed ID: 9433375
[TBL] [Abstract][Full Text] [Related]
59. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
60. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.
Frankel SR; Eardley A; Heller G; Berman E; Miller WH; Dmitrovsky E; Warrell RP
Ann Intern Med; 1994 Feb; 120(4):278-86. PubMed ID: 8291820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
